English  |  正體中文  |  简体中文  |  Items with full text/Total items : 18374/20630 (89%)
Visitors : 16492126      Online Users : 220
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/31765

    標題: Risk factors associated with the development of seizures among adult patients treated with ertapenem: A matched case-control study
    作者: Lee, Yi-Chien
    Huang, Yun-Jhong
    Hung, Miao-Chiu
    Hung, Sheng-Che
    Hsiao, Chih-Yen
    Cho, Hui-Ling
    Lai, Li-Fen
    Tong, Show-Hwa
    Wang, Jann-Tay
    貢獻者: Ditmanson Med FdnChia Yi Christian Hosp, Dept Internal Med
    Chia Nan Univ Pharm & Sci, Dept Sports Management
    Ditmanson Med FdnChia Yi Christian Hosp, Dept Colorectal Surg
    Taipei Vet Gen Hosp, Dept Pediat
    Taipei Vet Gen Hosp, Dept Radiol
    Natl Yang Ming Univ, Sch Med
    Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm
    Ditmanson Med FdnChia Yi Christian Hosp, Dept Nursing
    Ditmanson Med FdnChia Yi Christian Hosp, Dept Pharm
    Natl Taiwan Univ Hosp, Dept Internal Med
    關鍵字: Heart-Failure
    Febrile Seizures
    日期: 2017-07-31
    上傳時間: 2018-11-30 15:55:52 (UTC+8)
    出版者: Public Library Science
    摘要: Objective The purpose of this study is to compare the characteristics of those ertapenem-treated adult patients with and without development of seizures, and identify the associated factors for the development of seizures. Methods This retrospective study was conducted at Chia-Yi Christian Hospital from January 2012 to December 2014. Patients developing seizures during their ertapenem treatment course were identified as case patients. Those without seizures who had received ertapenem for at least five days were considered as the pool of control patients. For each case patient, four matched patients from the control pool were randomly selected as the final control group, based on age, gender, and the date of ertapenem prescription. Results A total of 1706 ertapenem-treated patients were identified, 33 (1.9%) individuals developed seizures with the enrollment of 132 matched control patients. Among these 33 patients, the average age was 79.3 +/- 7.5 years, and 20 (60.6%) were male. The mean Charlson co -morbidity score was 4.5 +/- 2.4, and the first episode of seizure happened 3.3 +/- 2.6 days after receiving ertapenem. In multivariate logistic regression analysis, the independent predictors associated with the development of ertapenem-associated seizures were old stroke (OR, 14.36; 95% CI, 4.38-47.02; p < 0.0001), undergoing brain images within one year prior to the admission (OR, 5.73; 95% CI, 1.78-18.43; p = 0.0034), low hemoglobin level (OR, 3.88; 95% CI, 1.28-12.75; p = 0.0165) and low platelet count (OR, 4,94; 95% CI, 1.56-15.68; p = 0.0067) at presentations, and protective factors against the development of seizures were heart failure (OR, 0.04; 95% CI, 0.00-0.63; p = 0.0222), concomitant use of steroids (OR, 0.19; 95% CI, 0.05-0.77; p = 0.0201), or antiplatelet agents (OR, 0.12; 95% CI, 0.02-0.63, p = 0.0123) with ertapenem. Conclusions The development of ertapenem-associated seizures may occur more frequently and much earlier due to its widespread use in treating drug -resistant pathogens, especially when these pathogens emerged worldwide.Our study would help physician to estimate the risk of developing seizure among patients receiving ertapenem.
    關聯: Plos One, v.12, n.7, e0182046
    Appears in Collections:[醫務管理系(所)] 期刊論文
    [運動管理系] 期刊論文

    Files in This Item:

    File Description SizeFormat
    10.1371-journal.pone.0182046.pdf1437KbAdobe PDF0View/Open

    All items in CNU IR are protected by copyright, with all rights reserved.

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback